Osugacestat is under clinical development by Ayala Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Osugacestat’s likelihood of approval (LoA) and phase transition for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) took place on 19 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Osugacestat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Osugacestat overview

AL101 (BMS-906024) is under development for the treatment of recurrent or metastatic adenoid cystic carcinoma, metastatic triple negative breast cancer,T-cell acute lymphoblastic leukemia and soft tissue tumors. The drug candidate is administered intravenously. It acts by targeting pan-notch gamma-secretase.

It was also under development for squamous non-small cell lung cancer, pancreatic cancer, ovarian cancer, melanoma and hematological malignancies including precursor cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma and colorectal cancer.

Ayala Pharmaceuticals overview

Ayala Pharmaceuticals is a clinical-stage bio-pharmaceutical company which develops novel drugs for defined cancers. Its lead product candidate AL101 and AL102 to treat cancers. The products render different cancers like desmoid tumors, adenoid cystic carcinoma (ACC), triple negative breast cancer (TNBC) and T-cell acute lymphoblastic leukemia (T-ALL). Ayala Pharmaceuticals desmoid tumors arise in upper and lower extremities, abdominal wall, head and neck area, mesenteric root and chest wall of the body. In addition, it also focuses on inhibiting the Notch activating pathway with best-in-class gamma secretase inhibitors (GSIs). The company has operations in Israel and the US. Ayala Pharmaceuticals is headquartered in Wilmington, Delaware, the US.

Quick View Osugacestat LOA Data

Report Segments
  • Innovator
Drug Name
  • Osugacestat
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.